New transplant recipe aims to tame Graft-Versus-Host disease
NCT ID NCT05805605
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. Participants receive drugs to suppress the immune system after transplant to further reduce this risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant (from a donor) with chemotherapy, radiation, and immune-suppressing drugs
- What this could lead to
- If successful, this approach could offer a safer way to perform stem cell transplants for people with blood cancers, potentially reducing severe side effects like graft-versus-host disease.
- What could go wrong
- This is a Phase 2 trial with a moderate number of participants. The transplant carries risks of infection, organ damage, and graft-versus-host disease, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Can a modified interferon rein in early myelofibrosis?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Can pressurized oxygen boost cord blood transplants?